Cargando…

AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation

SIMPLE SUMMARY: We evaluated the effect of AFP response to locoregional therapy (LRT) on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation. The enrolled patients were divided into four groups according to LRT and AFP response to LRT. The nonresponse group had...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, I-Hsuan, Hsu, Chien-Chin, Yong, Chee-Chien, Cheng, Yu-Fan, Wang, Chih-Chi, Lin, Chih-Che, Chen, Chao-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001078/
https://www.ncbi.nlm.nih.gov/pubmed/36900345
http://dx.doi.org/10.3390/cancers15051551
_version_ 1784904044888719360
author Chen, I-Hsuan
Hsu, Chien-Chin
Yong, Chee-Chien
Cheng, Yu-Fan
Wang, Chih-Chi
Lin, Chih-Che
Chen, Chao-Long
author_facet Chen, I-Hsuan
Hsu, Chien-Chin
Yong, Chee-Chien
Cheng, Yu-Fan
Wang, Chih-Chi
Lin, Chih-Che
Chen, Chao-Long
author_sort Chen, I-Hsuan
collection PubMed
description SIMPLE SUMMARY: We evaluated the effect of AFP response to locoregional therapy (LRT) on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation. The enrolled patients were divided into four groups according to LRT and AFP response to LRT. The nonresponse group had the highest 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the lowest 5-year cumulative recurrence rates among the four groups. The 5-year cumulative recurrence rates of the partial-response group (AFP response was not back to the normal level) was comparable to the control group. AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT and also to clarify the efficacy of LRT. A better prognosis can be expected if a partial AFP response of over 15% is achieved. ABSTRACT: (1) Background: Alpha-fetoprotein (AFP) has been incorporated into the selection criteria of liver transplantation and been used to predict the outcome of hepatocellular carcinoma (HCC) recurrence. Locoregional therapy (LRT) is recommended for bridging or downstaging in HCC patients listed for liver transplantation. The aim of this study was to evaluate the effect of the AFP response to LRT on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation (LDLT). (2) Methods: This retrospective study included 370 HCC LDLT recipients with pretransplant LRT from 2000 to 2016. The patients were divided into four groups according to AFP response to LRT. (3) Results: The nonresponse group had the worst 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the best 5-year cumulative recurrence rate among the four groups. The 5-year cumulative recurrence rate of the partial-response group (AFP response was over 15% lower) was comparable to the control group. (4) Conclusions: AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT. If a partial AFP response of over 15% declineis achieved, a comparable result to the control can be expected.
format Online
Article
Text
id pubmed-10001078
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100010782023-03-11 AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation Chen, I-Hsuan Hsu, Chien-Chin Yong, Chee-Chien Cheng, Yu-Fan Wang, Chih-Chi Lin, Chih-Che Chen, Chao-Long Cancers (Basel) Article SIMPLE SUMMARY: We evaluated the effect of AFP response to locoregional therapy (LRT) on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation. The enrolled patients were divided into four groups according to LRT and AFP response to LRT. The nonresponse group had the highest 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the lowest 5-year cumulative recurrence rates among the four groups. The 5-year cumulative recurrence rates of the partial-response group (AFP response was not back to the normal level) was comparable to the control group. AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT and also to clarify the efficacy of LRT. A better prognosis can be expected if a partial AFP response of over 15% is achieved. ABSTRACT: (1) Background: Alpha-fetoprotein (AFP) has been incorporated into the selection criteria of liver transplantation and been used to predict the outcome of hepatocellular carcinoma (HCC) recurrence. Locoregional therapy (LRT) is recommended for bridging or downstaging in HCC patients listed for liver transplantation. The aim of this study was to evaluate the effect of the AFP response to LRT on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation (LDLT). (2) Methods: This retrospective study included 370 HCC LDLT recipients with pretransplant LRT from 2000 to 2016. The patients were divided into four groups according to AFP response to LRT. (3) Results: The nonresponse group had the worst 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the best 5-year cumulative recurrence rate among the four groups. The 5-year cumulative recurrence rate of the partial-response group (AFP response was over 15% lower) was comparable to the control group. (4) Conclusions: AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT. If a partial AFP response of over 15% declineis achieved, a comparable result to the control can be expected. MDPI 2023-03-01 /pmc/articles/PMC10001078/ /pubmed/36900345 http://dx.doi.org/10.3390/cancers15051551 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, I-Hsuan
Hsu, Chien-Chin
Yong, Chee-Chien
Cheng, Yu-Fan
Wang, Chih-Chi
Lin, Chih-Che
Chen, Chao-Long
AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
title AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
title_full AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
title_fullStr AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
title_full_unstemmed AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
title_short AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
title_sort afp response to locoregional therapy can stratify the risk of tumor recurrence in hcc patients after living donor liver transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001078/
https://www.ncbi.nlm.nih.gov/pubmed/36900345
http://dx.doi.org/10.3390/cancers15051551
work_keys_str_mv AT chenihsuan afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation
AT hsuchienchin afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation
AT yongcheechien afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation
AT chengyufan afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation
AT wangchihchi afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation
AT linchihche afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation
AT chenchaolong afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation